Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-26T17:41:01.469Z Has data issue: false hasContentIssue false

Chapter 17 - Head and Neck Cancer

Published online by Cambridge University Press:  23 October 2024

By
Caitlin M. Coviello ,
Erich M. Sturgis  and
Kristina R. Dahlstrom
Edited by
Laurie J. Mckenzie  and
Denise R. Nebgen
Laurie J. Mckenzie
Affiliation:
University of Texas MD Anderson Cancer Center, Houston
Denise R. Nebgen
Affiliation:
University of Texas MD Anderson Cancer Center, Houston
Get access

Summary

Human papillomavirus (HPV) is a leading cause of cancer and cancer-related death in women, overwhelmingly attributed to rates of cervical cancer in low and middle-income countries. However, in the U.S., HPV-related oropharyngeal cancer (OPC) has surpassed cervical cancer as the most common HPV-related cancer, although it is much more common (5-fold) in men than women. Similar to other head and neck cancer, HPV-related OPCs typically require complex multidisciplinary treatments often with major lifelong sequelae. However, HPV-related OPCs have much better cancer cure rates and lower second primary malignancy rates than tobacco-related head and neck cancer. Unique patterns of second primary malignancies, related to HPV exposures, are often a concern for female patients. This chapter will focus on HPV-related OPC, its associations with other malignancies in women, and prevention / screening recommendations and potentials for women with HPV-related OPC.

Keywords

human papillomavirusoropharyngeal cancerhead and neck cancertonsil cancerbase of tongue cancer
Type
Chapter
Information
Caring for the Female Cancer Patient
Gynecologic Considerations
 , pp. 284 - 303
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mourad, W. F., Hu, K. S., Choi, W. H., et al. General Principles and Management Cancer of the Oropharynx. In Harrison L. B., Sessions R. B., Kies M. S. (Eds.), Head and Neck Cancer: A Multidisciplinary Approach. Wolters Kluwer; 2013, pp. 373–440.Google Scholar
Kreimer, A. R., Clifford, G. M., Boyle, P., Franceschi, S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467–75. https://doi.org/10.1158/1055-9965.EPI-04-0551.CrossRefGoogle ScholarPubMed
Syrjänen, S., Lodi, G., von Bültzingslöwen, I., et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: A systematic review. Oral Dis. 2011;17:58–72. https://doi.org/10.1111/J.1601-0825.2011.01792.X.CrossRefGoogle ScholarPubMed
Sturgis, E. M., Cinciripini, P. M. Trends in head and neck cancer incidence in relation to smoking prevalence: An emerging epidemic of human papillomavirus-associated cancer? Cancer. 2007;110:1429–35. https://doi.org/10.1002/CNCR.22963.CrossRefGoogle Scholar
Chaturvedi, A. K., Engels, E. A., Pfeiffer, R. M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301. https://doi.org/10.1200/JCO.2011.36.4596.CrossRefGoogle ScholarPubMed
Tota, J. E., Best, A. F., Zumsteg, Z. S., et al. Evolution of the oropharynx cancer epidemic in the United States: Moderation of increasing incidence in younger individuals and shift in the burden to older individuals. Journal of Clinical Oncology 2019;37:1538–46. https://doi.org/10.1200/JCO.19.00370.CrossRefGoogle ScholarPubMed
Van Dyne, E. A., Henley, S. J., Saraiya, M., et al. Trends in Human Papillomavirus–Associated Cancer – United States, 1999-2015. Morbidity and Mortality Weekly Report: US Department of Health and Human Services, CDC 2018;67.Google ScholarPubMed
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2021 submission data (1999–2019): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, released in June 2022. n.d. https://gis.cdc.gov/Cancer/USCS/#/RiskFactors/ (accessed October 10, 2022).Google Scholar
Dahlstrom, K. R., Bell, D., Hanby, D., et al. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. Oral Oncol. 2015;51:832–8. https://doi.org/10.1016/j.oraloncology.2015.06.005.CrossRefGoogle ScholarPubMed
Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. Cancer Statistics, 2022. CA Cancer J Clin. 2022;72:7–33.CrossRefGoogle Scholar
Rettig, E. M., Fakhry, C., Khararjian, A., Westra, W. H. Age profile of patients with oropharyngeal squamous cell carcinoma. JAMA Otolaryngology–Head & Neck Surgery. 2018;144:538–9. https://doi.org/10.1001/JAMAOTO.2018.0310.CrossRefGoogle ScholarPubMed
HPV-Associated Cancer Diagnosis by Age | CDC n.d. www.cdc.gov/cancer/hpv/statistics/age.htm (accessed September 16, 2022).Google Scholar
Mahal, B. A., Catalano, P. J., Haddad, R. I., et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancer in the United States. Cancer, Epidemiology, Biomarkers, and Prevention. 2019;28:1660–7. https://doi.org/10.1158/1055-9965.EPI-19-0038.CrossRefGoogle ScholarPubMed
Gan, S. J., Dahlstrom, K. R., Peck, B. W., et al. Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancer versus index nonoropharyngeal head and neck cancer. Cancer. 2013:2593–601. https://doi.org/10.1002/cncr.28107.CrossRefGoogle Scholar
Dahlstrom, K. R., Bell, D., Hanby, D., et al. Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. Oral Oncol. 2015;51(9):832–8. https://doi.org/10.1016/j.oraloncology.2015.06.005.CrossRefGoogle ScholarPubMed
Rotsides, J. M., Oliver, J. R., Moses, L. E., et al. Socioeconomic and racial disparities and survival of human papillomavirus-associated oropharyngeal squamous cell carcinoma. Otolaryngology-Head and Neck Surgery. 2021;164:131–8. https://doi.org/10.1177/0194599820935853.CrossRefGoogle ScholarPubMed
Souza, G. d’, Wentz, A., Kluz, N., et al. Sex differences in risk factors and natural history of oral human papillomavirus infection. J Infect Dis. 2016;213:1893–6. https://doi.org/10.1093/infdis/jiw063.CrossRefGoogle ScholarPubMed
Lewis, R. M., Gargano, J. W., Unger, E. R., Querec, T. D., Markowitz, L. E. Genital human papillomavirus prevalence over the lifespan among females and males in a national cross-sectional survey, United States, 2013–2016. Sex Transm Dis. 2021;48:855–63. https://doi.org/10.1097/OLQ.0000000000001447.CrossRefGoogle Scholar
Chesson, H. W., Dunne, E. F., Hariri, S., Markowitz, L. E. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41:660–4. https://doi.org/10.1097/OLQ.0000000000000193.CrossRefGoogle ScholarPubMed
Chaturvedi, A. K., Graubard, B. I., Broutian, T., et al. Prevalence of oral HPV infection in unvaccinated men and women in the United States, 2009–2016. JAMA – Journal of the American Medical Association. 2019;322:977–9. https://doi.org/10.1001/JAMA.2019.10508.CrossRefGoogle ScholarPubMed
Chaturvedi, A. K., Graubard, B. I., Broutian, T., et al. NHANES 2009–2012 findings: Association of sexual behaviors with higher prevalence of oral oncogenic human papillomavirus infections in U.S. men. Cancer Res. 2015;75:2468–77. https://doi.org/10.1158/0008-5472.CAN-14-2843.CrossRefGoogle ScholarPubMed
Giuliano, A. R., Nyitray, A. G., Kreimer, A. R., et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136:2752–60. https://doi.org/10.1002/IJC.29082.CrossRefGoogle ScholarPubMed
Bleeker, M. C. G., Hogewoning, C. J. A., Berkhof, J., et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clinical Infectious Diseases. 2005;41:612–20. https://doi.org/10.1086/431978/2/41-5-612-TBL005.GIF.CrossRefGoogle ScholarPubMed
Saunders, C. L., Meads, C., Abel, G. A., Lyratzopoulos, G. Associations between sexual orientation and overall and site-specific diagnosis of cancer: Evidence from two national patient surveys in England. J Clin Oncol. 2017;35:3654–61. https://doi.org/10.1200/JCO.CrossRefGoogle ScholarPubMed
Gillison, M. L. Oropharyngeal cancer: A potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol. 2009;21:439–44. https://doi.org/10.1097/CCO.0B013E32832F3E1B.CrossRefGoogle ScholarPubMed
Gillison, M. L., Broutian, T., Pickard, R. K. L., et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307:693–703. https://doi.org/10.1001/JAMA.2012.101.CrossRefGoogle ScholarPubMed
Smith, E. M., Rubenstein, L. M., Haugen, T. H., Hamsikova, E., Turek, L. P. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancer. Cancer Causes Control. 2010;21:1369–78. https://doi.org/10.1007/S10552-010-9564-Z.CrossRefGoogle Scholar
Applebaum, K. M., Furniss, C. S., Zeka, A., et al. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst. 2007;99:1801–10. https://doi.org/10.1093/JNCI/DJM233.CrossRefGoogle ScholarPubMed
Marks, M. A., Chaturvedi, A. K., Kelsey, K., et al. Association of marijuana smoking with oropharyngeal and oral tongue cancer: Pooled analysis from the INHANCE consortium. Cancer, Epidemiology, Biomarkers, & Prevention. 2014;23:160–71. https://doi.org/10.1158/1055-9965.EPI-13-0181.CrossRefGoogle ScholarPubMed
Morris, L. G. T., Sikora, A. G., Patel, S. G., Hayes, R. B., Ganly, I. Second primary cancer after an index head and neck cancer: Subsite-specific trends in the era of human papillomavirus – Associated oropharyngeal cancer. Journal of Clinical Oncology. 2011;29:739–46. https://doi.org/10.1200/JCO.2010.31.8311.CrossRefGoogle ScholarPubMed
Sturgis, E. M., Miller, R. H. Second primary malignancies in the head and neck cancer patient. Rhinology & Laryngology. 1995;104:946. https://doi.org/0.1177/000348949510401206.CrossRefGoogle ScholarPubMed
Do, K. -A., Johnson, M. M., Lee, J. J., et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004;101:2837–42. https://doi.org/10.1002/cncr.20714.CrossRefGoogle Scholar
Walboomers, J. M., Jacobs, M. v., Manos, M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology. 1999;189:12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<2::aid-path431>3.0.CO;2-F.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Sutton, B. C., Allen, R. A., Moore, W. E., Dunn, S. T. Distribution of human papillomavirus genotypes in invasive squamous carcinoma of the vulva. Modern Pathology. 2008;21:3:45–54. https://doi.org/10.1038/modpathol.3801010.CrossRefGoogle ScholarPubMed
Steenbergen, R. D. M., de Wilde, J., Wilting, S. M., et al. HPV-mediated transformation of the anogenital tract. Journal of Clinical Virology 2005;32:25–33. https://doi.org/10.1016/J.JCV.2004.11.019.CrossRefGoogle ScholarPubMed
Tornesello, M. L., Duraturo, M. L., Losito, S., et al. Human papillomavirus genotypes and HPV16 variants in penile carcinoma. Int J Cancer. 2008;122:132–7. https://doi.org/10.1002/ijc.23062.CrossRefGoogle ScholarPubMed
Sikora, A. G., Morris, L. G., Sturgis, E. M. Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg. 2009;135:402–5. https://doi.org/10.1001/archoto.2009.19.CrossRefGoogle ScholarPubMed
Rietbergen, M. M., van Bokhoven, A. A. J. D., Lissenberg-Witte, B. I., et al. Epidemiologic associations of HPV-positive oropharyngeal cancer and (pre)cancerous cervical lesions. Int J Cancer. 2018;143:283–8. https://doi.org/10.1002/ijc.31315.CrossRefGoogle ScholarPubMed
Ebisch, R. M. F., Rutten, D. W. E., IntHout, J., et al. Long-lasting increased risk of human papillomavirus–related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: A population-based cohort study. Journal of Clinical Oncology. 2017;35:2542–50. https://doi.org/10.1200/JCO.2016.71.4543.CrossRefGoogle ScholarPubMed
Ragin, C. C. R., Taioli, E. Second primary head and neck tumor risk in patients with cervical cancer: SEER data analysis. Head Neck. 2007;30:58–66. https://doi.org/10.1002/hed.20663.CrossRefGoogle Scholar
Jani, K. S., Lu, S.-E., Murphy, J. D., et al. Malignancies diagnosed before and after anal squamous cell carcinomas: A SEER registry analysis. Cancer Med. 2021;10:3575–83. https://doi.org/10.1002/cam4.3909.CrossRefGoogle ScholarPubMed
Suk, R., Mahale, P., Sonawane, K., et al. Trends in risks for second primary cancer associated with index human papillomavirus-associated cancer. JAMA Netw Open. 2018;1:e181999. https://doi.org/10.1001/jamanetworkopen.2018.1999.CrossRefGoogle Scholar
Tsao, A. S., Papadimitrakopoulou, V., Lin, H., et al. Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer. 2016;11:1–9. https://doi.org/10.1186/s13027-016-0066-9.CrossRefGoogle ScholarPubMed
D’Souza, G., Gross, N. D., Pai, S. I., et al. Oral Human Papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. Journal of Clinical Oncology. 2014;32:2408–15. https://doi.org/10.1200/JCO.2014.55.1341.Google ScholarPubMed
Mirghani, H., Strugis, E. M., Auperin, A., Monsonego, J., Blanchard, P. Is there an increased risk of cancer among spouses of patients with HPV-related cancer: A systematic Review. Oral Oncol. 2017;67:138–45. https://doi.org/10.1016/j.oraloncology.2017.02.024.CrossRefGoogle ScholarPubMed
Meites, E., Szilagyi, P. G., Chesson, H. W., et al. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices. American Journal of Transplantation. 2019;19:3202–6. https://doi.org/10.1111/ajt.15633.CrossRefGoogle Scholar
FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old | FDA n.d. www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old (accessed August 21, 2022).Google Scholar
Petrosky, E., Bocchini, J. A., Hariri, S., et al. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.Google ScholarPubMed
Lehtinen, M., Dillner, J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol. 2013;10:400–10. https://doi.org/10.1038/nrclinonc.2013.84.CrossRefGoogle ScholarPubMed
Drolet, M., Bénard, É., Pérez, N., et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. The Lancet. 2019;394:497–509. https://doi.org/10.1016/S0140-6736(19)30298-3.CrossRefGoogle ScholarPubMed
Brisson, M., Kim, J. J., Canfell, K., et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: A comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet. 2020;395:575–90. https://doi.org/10.1016/S0140-6736(20)30068-4.CrossRefGoogle ScholarPubMed
Markowitz, L. E., Naleway, A. L., Lewis, R. M., et al. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination. Vaccine. 2019;37:3918–24. https://doi.org/10.1016/j.vaccine.2019.04.099.CrossRefGoogle ScholarPubMed
Michalczyk, K., Misiek, M., Chudecka-Głaz, A . Can adjuvant HPV vaccination be helpful in the prevention of persistent/recurrent cervical dysplasia after surgical treatment? A literature review. Cancer. 2022;14:4352. https://doi.org/10.3390/CANCER14184352.CrossRefGoogle ScholarPubMed
di Donato, V., Caruso, G., Petrillo, M., et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: A meta-analysis. Vaccines (Basel). 2021;9(5):410. https://doi.org/10.3390/VACCINES9050410.Google Scholar
Tang, J., Li, M., Zhao, C., et al. Therapeutic DNA vaccines against HPV-related malignancies: Promising leads from clinical trials. Viruses. 2022;14(2): 239. https://doi.org/10.3390/V14020239.Google Scholar
Dahlstrom, K. R., Anderson, K. S., Guo, M., et al. Screening for HPV-related oropharyngeal, anal, and penile cancer in middle-aged men: Initial report from the HOUSTON clinical trial. Oral Oncol. 2021;120. https://doi.org/10.1016/j.oraloncology.2021.105397.CrossRefGoogle ScholarPubMed
Bosch, F. X., Broker, T. R., Forman, D., et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 7:H1–31. https://doi.org/10.1016/j.vaccine.2013.10.003.CrossRefGoogle ScholarPubMed
Kreimer, A. R., Pierce Campbell, C. M., Lin, H. Y., et al. Incidence and clearance of oral human papillomavirus infection in men: The HIM cohort study. The Lancet 2013;382:877–87. https://doi.org/10.1016/S0140-6736(13)60809-0.CrossRefGoogle ScholarPubMed
D’Souza, G., Clemens, G., Strickler, H. D., et al. Long-term Persistence of oral HPV over 7 years of follow-up. JNCI Cancer Spectr. 2020;4(5):pkaa047. https://doi.org/10.1093/JNCICS/PKAA047.CrossRefGoogle ScholarPubMed
Morais, E., Kothari, S., Roberts, C., et al. Oral human papillomavirus (HPV) and associated factors among healthy populations: The design of the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study. Contemp Clin Trials. 2022;115. https://doi.org/10.1016/J.CCT.2021.106630.CrossRefGoogle ScholarPubMed
Anderson, K. S., Dahlstrom, K. R., Cheng, J. N., et al. HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. Oral Oncol. 2015;51. https://doi.org/10.1016/j.oraloncology.2015.04.011.CrossRefGoogle ScholarPubMed
Dahlstrom, K. R., Anderson, K. S., Field, M. S., et al. Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus–related oropharyngeal cancer. Cancer. 2017;123. https://doi.org/10.1002/cncr.30955.CrossRefGoogle ScholarPubMed
Kreimer, A. R., Johansson, M., Waterboer, T., et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013;31:2708–15. https://doi.org/10.1200/JCO.2012.47.2738.CrossRefGoogle ScholarPubMed
Kreimer, A. R., Johansson, M., Yanik, E. L., et al. Kinetics of the human papillomavirus type 16 E6 antibody response prior to oropharyngeal cancer. J Natl Cancer Inst. 2017;109. https://doi.org/10.1093/JNCI/DJX005.CrossRefGoogle ScholarPubMed
Hibbert, J., Halec, G., Baaken, D., Waterboer, T., Brenner, N. Sensitivity and specificity of human papillomavirus (HPV) 16 early antigen serology for HPV-driven oropharyngeal cancer: A systematic literature review and meta-analysis. Cancer (Basel). 2021;13:3010.CrossRefGoogle ScholarPubMed
Robbins, H. A., Ferreiro-Iglesias, A., Waterboer, T., et al. Absolute risk of oropharyngeal cancer after an HPV16-E6 serology test and potential implications for screening: Results from the human papillomavirus cancer cohort consortium. J Clin Oncol. 2022:JCO2101785. https://doi.org/10.1200/JCO.21.01785.CrossRefGoogle Scholar
Chera, B. S., Kumar, S., Beaty, B. T., et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. Clinical Cancer Research. 2019;25:4682–90.CrossRefGoogle ScholarPubMed
Chera, B. S., Kumar, S., Shen, C., et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. Journal of Clinical Oncology. 2020;38:1050–8. https://doi.org/10.1200/JCO.19.02444.CrossRefGoogle ScholarPubMed
Rettig, E. M., Faden, D. L., Sandhu, S., et al. Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer. Int J Cancer. 2022;151:1081–5. https://doi.org/10.1002/ijc.33996.CrossRefGoogle ScholarPubMed
Scott‐Wittenborn, N., D’Souza, G., Aygun, N., et al. Feasibility of clinical evaluation of individuals with increased risk for HPV-associated oropharynx cancer. Head Neck. 2022. https://doi.org/10.1002/HED.27212.CrossRefGoogle Scholar
Waterboer, T., Brenner, N., Gallagher, R., et al. Early detection of human papillomavirus–driven oropharyngeal cancer using serology from the study of prevention of anal cancer. JAMA Oncol. 2020;6:1806–8. https://doi.org/10.1001/JAMAONCOL.2020.4527.CrossRefGoogle Scholar
Busch, C. J., Hoffmann, A. S., Viarisio, D., et al. Detection of stage I HPV-driven oropharyngeal cancer in asymptomatic individuals in the Hamburg City Health Study using HPV16 E6 serology: A proof-of-concept study. EClinicalMedicine. 2022;53. https://doi.org/10.1016/J.ECLINM.2022.101659.CrossRefGoogle Scholar
Tota, J. E., Gillison, M. L., Katki, H. A., et al. Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. Cancer. 2019;125:4407–16. https://doi.org/10.1002/CNCR.32412.CrossRefGoogle ScholarPubMed
McIlwain, W. R., Sood, A. J., Nguyen, S. A., Day, T. A. Initial symptoms in patients with HPV-positive and HPV-negative oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg. 2014;140:441–7. https://doi.org/10.1001/jamaoto.2014.141.CrossRefGoogle ScholarPubMed
Ang, K., Harris, J., Wheeler, R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35. https://doi.org/10.1056/NEJMoa0912217.CrossRefGoogle ScholarPubMed
Fakhry, C., Westra, W. H., Li, S., et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal National Cancer Institute. 2008;100:261–9.CrossRefGoogle ScholarPubMed
Amin, M. B., Edge, S. B., Greene, F. L., et al. (Eds.). AJCC Cancer Staging Manual. 8th ed. Springer; 2017.Google ScholarPubMed
Petrelli, F., Luciana, A., Ghidini, A., et al. Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis. Head Neck. 2022;44:1255–66.CrossRefGoogle ScholarPubMed
Mehanna, H., Robinson, M., Hartley, A., et al. Articles radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label andomized controlled phase 3 trial. The Lancet. 2019;393:51–60. https://doi.org/10.1016/S0140-6736(18)32752-1.CrossRefGoogle ScholarPubMed
80. NCCN Guidelines Version 2.2022. National Comprehensive Cancer Network 2022. www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed September 26, 2022).Google Scholar
Quan, D. L., Sukari, A., Nagasaka, M., et al. Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head Neck. 2021;43:3681–98. https://doi.org/10.1002/hed.26829.CrossRefGoogle ScholarPubMed
Martin, A., Murray, L., Sethugavalar, B., et al. Changes in patient-reported swallow function in the long term after chemoradiotherapy for oropharyngeal carcinoma. Clin Oncol (R Coll Radiol). 2018;30:756–63. https://doi.org/10.1016/J.CLON.2018.06.013.CrossRefGoogle Scholar
Dahlstrom, K. R., Song, J., Thall, P. F., et al. Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. Cancer. 2021;127:1228–37.CrossRefGoogle ScholarPubMed
Mir, O., Berveiller, P., Ropert, S., Goffinet, F. F., Goldwasser, F. F. Use of platinum derivatives during pregnancy. Cancer. 2008;113:3069–74. https://doi.org/10.1002/cncr.23935.CrossRefGoogle ScholarPubMed
Hepner, A., Negrini, D., Hase, A., et al. Cancer during pregnancy: The oncologist overview. Review World J Oncol. 2019;10:28–34. https://doi.org/10.14740/wjon1177.CrossRefGoogle ScholarPubMed
Zhang, Y., Fakhry, C., D’Souza, G. Projected association of human papillomavirus vaccination with oropharynx cancer incidence in the US, 2020–2045. JAMA Oncol. 2021;7. https://doi.org/10.1001/JAMAONCOL.2021.2907.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×